Advanced Oncotherapy PLC Investor Day Update (4026C)
19 October 2020 - 5:00PM
UK Regulatory
TIDMAVO
RNS Number : 4026C
Advanced Oncotherapy PLC
19 October 2020
19 October 2020
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
Investor Day Update
Advanced Oncotherapy (AIM: AVO), the developer of
next-generation proton therapy systems for cancer treatment, will
today hold its Investor Day presentation at 14:00 BST. The Company
will be hosting a presentation accessible to all through the
digital online platform Investor Meet Company, via the following
link:
https://www.investormeetcompany.com/advanced-oncotherapy-plc/register-investor
.
A recording of the presentation and a copy of the slide deck
will be available on the Investor Meet Company platform shortly
after the live presentation.
Today's Investor Day presentation will be held by the Company's
Senior Management team, where they will provide (i) an update on
the current dynamics within the proton therapy market, (ii) an
overview of the technical and potential treatment benefits of
Advanced Oncotherapy's proprietary LIGHT proton therapy system, and
(iii) a review of the Company's recent progress, proposed business
model and outlook. In particular:
-- The Company will discuss the broader market potential for
proton therapy and outline how its LIGHT system could accelerate
the adoption of proton therapy as a treatment modality for a number
of different cancer indications.
-- The Company will discuss how the LIGHT system can potentially
be adapted for FLASH delivery of protons, an emerging mode of
proton therapy treatment that utilises ultra-high dose rates -
potentially providing the same treatment effects of typical proton
radiation sessions - but in a fraction of the time. This may not
only dramatically increase the rate at which patients can be
treated, but also the types of tumour that are considered suitable
for proton therapy. The potential of the LIGHT system to deliver
mini-beams will also be outlined as well as how this could allow
treatments to be highly sculpted to address irregular shaped
tumours.
-- The Company expects to have a fully operational LIGHT system,
at Daresbury, with a beam energy suitable to support patient
treatment during 2021. Actual treatment of patients, which is
expected to occur shortly after this LIGHT machine is fully
operational, remains dependent on the Company's clinical partner,
University Hospital Birmingham.
-- The Company will discuss how the modularity of the LIGHT
system is the foundation of a differentiated and profitable
business model: the opportunity to use the LIGHT system as
collateral in financing transactions is a unique selling point in
proton therapy and is expected to (i) support the funding for
manufacturing new machines, (ii) facilitate the acquisition of the
technology by customers, (iii) accelerate the pipeline of
commercial orders and (iv) create a sustainable and diversified
source of cash-flows.
-- Following the Company's successful partnership efforts to
date, the Board of Advanced Oncotherapy expect that further
commercial collaborations and purchase orders will be signed in
2021 given the Company's strong pipeline of global
opportunities.
-- Recent expansion of the Company's partnership with the
Cleveland Clinic, which will now be able to refer cancer patients
from its London facility to Advanced Oncotherapy's London Clinic
site in Harley Street, is expected to result in more patients being
treated at the London Clinic site, from which the Company would
receive a share of the profits.
Nicolas Serandour, CEO of Advanced Oncotherapy, said:
"At today's presentation, we will reaffirm our view from the
interim results that, although there have been headwinds caused as
a result of Covid-19 pandemic during 2020, the Company has made
strong progress and now has all the key high-precision components
of the accelerator in place at Daresbury. 2021 is set to be an
exciting year for the Company as we expect to have a fully
operational LIGHT system with a 230MeV beam, which is the beam
energy needed to treat patients. We also expect to sign further
commercial agreements for new machines as we progress our robust
pipeline of opportunities."
- ENDS -
Advanced Oncotherapy plc www.avoplc.com
Dr. Michael Sinclair, Executive Chairman Tel: +44 (0) 20 3617 8728
Nicolas Serandour, CEO
Allenby Capital Limited (Nomad and Joint Broker)
Nick Athanas / Liz Kirchner (Corporate Finance) Tel: +44 (0) 20 3328 5656
Amrit Nahal / Matt Butlin (Sales & Broking)
SI Capital Ltd (Joint Broker)
Nick Emerson Tel: +44 (0) 1483 413 500
Jon Levinson Tel: +44 (0) 20 3871 4066
FTI Consulting (Financial PR & IR) advancedoncotherapy@fticonsulting.com
Simon Conway / Rob Winder Tel: +44 (0) 20 3727 1000
Notes for Editors
About Advanced Oncotherapy Plc www.avoplc.com
Advanced Oncotherapy, a UK headquartered company with offices in
London, Geneva, The Netherlands and in the USA, is a provider of
particle therapy with protons that harnesses the best in modern
technology. Advanced Oncotherapy's team "ADAM," based in Geneva,
focuses on the development of a proprietary proton accelerator
called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's
compact configuration delivers proton beams in a way that
facilitates greater precision and electronic control.
Advanced Oncotherapy will offer healthcare providers affordable
systems that will enable them to treat cancer with innovative
technology as well as expected lower treatment-related side
effects.
Advanced Oncotherapy continually monitors the market for any
emerging improvements in delivering proton therapy and actively
seeks working relationships with providers of these innovative
technologies. Through these relationships, the Company will remain
the prime provider of an innovative and cost-effective system for
particle therapy with protons.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDEAEEPFEPEFAA
(END) Dow Jones Newswires
October 19, 2020 02:00 ET (06:00 GMT)
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From Apr 2024 to May 2024
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From May 2023 to May 2024